The role of oxidative damage in tumoral conditions is well documented, with a large number of pathobiochemical pathways that lead to cellular neoplastic transformation and free radical DNA damage (2) . As the antioxidant material in serum is a mixture of different components, TAC is generally defined as an indicator of the antioxidant capacity of the body, reflecting the sum of all antioxidant substances present in serum (3) . In this respect, TAC could be a reliable biomarker for diagnostics and prognostics, especially in malignant diseases (4). But, from the results of the present study, it is obvious that there is a statistically significant increase in TAC levels in malignant patients, which is contrary to current literature data. Recent studies have proven that in neoplastic conditions, serum TAC levels decrease in conjunction with elevated lipid peroxidation levels. Decreased serum TAC levels have been shown in patients with breast cancer (5), hepatocellular carcinoma (6), multiple myeloma (7), gastrointestinal cancer (8), and endometrial cancer (9) . From this point of view, we think that it would have been worthwhile if the authors had discussed this controversial situation in their patient population.
In conclusion, based on the data mentioned above, we think that it is still early for TAC to be considered a useful marker for the differential diagnosis of biliary obstruction. Further randomized controlled studies with a larger number of participants are required to provide more evidence.
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In their comments under the heading of 'Serum total antioxidant capacity to discriminate benign from malignant causes of biliary obstruction' that published on September, 2014 issue of The Turkish Journal of Gastroenterology they mentioned about several issues that must be clarified. At first, commentators mentioned that they didn't understand whether the TAC is increased or decreased in the biliary obstruction and concluded that this confusion may be caused from methodology of the study because of abscence of a control group. We compared the malignant group with the benignant group and TAC levels were found higher in the malignant group. Ethically, we couldn't take bile samples from healthy controls so that we could not compare the tests levels of malignant and benignant groups with normal healthy group.
As defined in the manuscript and supported by the commentator/s, TAC levels decrease in many of cancer types (1) (2) (3) (4) (5) (6) . Levels were found as increased in the intermediate levels of sensitivity, specificity and accuracy in the malignant group of our study. And, these resultes were about the same not only for TAC but also for the other studied tests. So that, these tests were found useless for diffential diagnosis of malignant and benignant biliary disorders and did not proposed as a useful marker in the manuscript. Statistically, for a test, it is more important having a higher sensitivity, specificity and accuracy than having a higher mean.
As mentioned in our manuscript, TAC has never been studied on this topic, so that this study may accepted as a pilot study for differentation of malignant and benignant biliary disorders and certainly future large scaled studies are necassary on this topic.
